Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
616 hedge funds and large institutions have $1.57B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2019 Q4 according to their latest regulatory filings, with 616 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
497% more call options, than puts
Call options by funds: $48M | Put options by funds: $8.03M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$130M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$92.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$79M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$67.6M |
| 5 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
+$60.3M |
Top Sellers
BMY.RT Hedge Fund Activity: Q4 2019 in Review
616 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q4 2019, worth a combined $1.57B.
Buyers outnumbered sellers: 616 funds opened new BMY.RT positions and 0 closed out — a net gain of 616 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $130M.
- 616 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $1.57B of Bristol-Myers Squibb Company Contingent Value Rights stock for Q4 2019.
- 616 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q4 2019 and 0 closed out, a net change of +616 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q4 2019 was Laurion Capital Management, an estimated $130M added.
Based on aggregated 13F filings for Q4 2019.